Clovis Oncology Signs a License Agreement with 3B Pharmaceuticals for FAP-Targeted Radiopharmaceutical Program

Shots:

• 3BP to receive $12M up front, R&D milestones, an additional potential milestone with royalties on sales. Clovis to get rights to develop peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein alpha and will conduct global clinical studies excluding EU (inclusive of Russia, Turkey, and Israel) where 3BP retains rights
• Additionally, the companies agreed to collaborate for the discovery and development of radiopharmaceuticals for three additional targets using 3BP’s technology platform with a focus to expand Clovis’ portfolio
• FAP-targeted radiopharmaceuticals target multiple cancer indications, act by two modes of anti-tumor activity i.e, radiation crossfire and depletion of CAFs

Click here to­ read full press release/ article | Ref: Business wire | Image: Condit Exhibit